References
- LaForce FM. Anthrax. Clin Infect Dis 1994; 19(6): 1009–14
- World Health Organization. Health aspects of clinical and biological weapons. Geneva: World Health Organization, 1970:98–9
- Kournikakis B, Armour SJ, Boulet CA, et al. Risk assessment of anthrax threat letters. Suffield, Alberta, Canada: Defense Research Establishment Suffield, 2001; technical report No. DRES-TR-2001-048
- Friedlander AM. Anthrax. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical aspects of chemical and biological warfare. Textbook of military medicine. Part 1. Warfare, weaponry, and the casualty. Vol 3. Washington, DC: Office of the Surgeon General, Dept of the Army, 1997:467–78
- Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001;50(42): 909–19
- Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related in- halational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7(6): 933–44
- Craven RB, Barnes AM. Plague and tularemia. Infect Dis Clin North Am 1991;5(1): 165–75
- Ibrahim KH, Brown G, Wright DH, et al. Bacillus anthracis: medical issues of biologic warfare. Pharmacotherapy 1999;19(6): 690–701
- Speck RS, Wolochow H. Studies on the experimental epidemiology of respiratory infections. VIII. Experimental pneumonic plague in Macaccus rhesus. J Infect Dis 1957;100(1): 58–68
- Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283(17): 2281–90
- Smego RA, Frean J, Koornhof HJ. Yersiniosis I: microbiological and clinicoepidemiological aspects of plague and non-plague Yersinia infections. Eur J Clin Microbiol Infect Dis 1999; 18(1): 1–15
- Russell P, Eley SM, Green M, et al. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother 1998;41(2): 301–5
- Pneumonic plague—Arizona, 1992. JAMA 1992;268(16): 2146–7
- Titball RW, Leary SE. Plague. Br Med Bull 1998;54(3): 625–33
- Franz DR, Jahrling PE, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278(5): 399–411
- Chemical and biological weapons: the hazard to health. WHO Chron 1970;24(3): 99–108
- Miller RP, Bates JH. Pleuropulmonary tularemia: a review of 29 patients. Am Rev Respir Dis 1969;99(1): 31–41
- Evans ME, Gregory DW, Schaffner W, et al. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985;64(4): 251–69
- Byrd RP Jr, Vasquez J, Roy TM. Respiratory manifestations of tickborne diseases in the southeastern United States. South Med J 1997;90(1): 1–4
- Syrjala H, Karvonen J, Salminen A. Skin manifestations of tularemia: a study of 88 cases in northern Finland during 16 years (1967–1983). Acta Derm Venereol 1984;64(6): 513–6
- Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch Intern Med 1987;147(2): 265–8
- Roy TM, Fleming D, Anderson WH. Tularemic pneumonia mimicking Legionnaires' disease with false-positive direct fluorescent antibody stains for Legionella. South Med J 1989;82(11): 1429–31
- Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285(21): 2763–73
- Martin GJ, Marty AM. Clinicopathologic aspects of bacterial agents. Clin Lab Med 2001; 21 (3):513–48
- Milionis H, Christou L, Elisaf M. Cutaneous manifestations in brucellosis: case report and review of the literature. Infection 2000;28(2): 124–6
- Yagupsky P. Detection of brucellae in blood cultures. J Clin Microbiol 1999;37(11): 3437–42
- Malik GM. Early clinical response to different therapeutic regimens for human brucellosis. Am J Trop Med Hyg 1998;58(2): 190–1
- Joint FAO/WHO Expert Committee on Brucellosis. World Health Organ Tech Rep Ser 1986;740:1–132
- Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999;18(8): 535–8